These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38629360)

  • 1. Therapeutic Strategies to Improve the Treatment of Pleural Mesothelioma.
    Mirra L; Beretta GL; Lisini D; Marcianti A; Spampinato E; Corno C; Costantino M; Corsico A; Stella GM; Perego P
    Curr Med Chem; 2024 Apr; ():. PubMed ID: 38629360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches-a narrative review.
    Zolondick AA; Gaudino G; Xue J; Pass HI; Carbone M; Yang H
    Precis Cancer Med; 2021 Sep; 4():. PubMed ID: 35098108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular heterogeneity of malignant pleural mesotheliomas].
    Tranchant R; Montagne F; Jaurand MC; Jean D
    Bull Cancer; 2018 Jan; 105(1):35-45. PubMed ID: 29277245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature.
    Schumann SO; Kocher G; Minervini F
    J Thorac Dis; 2021 Apr; 13(4):2510-2523. PubMed ID: 34012597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles.
    Andujar P; Lacourt A; Brochard P; Pairon JC; Jaurand MC; Jean D
    J Toxicol Environ Health B Crit Rev; 2016; 19(5-6):151-172. PubMed ID: 27705546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP.
    Dubois F; Bazille C; Levallet J; Maille E; Brosseau S; Madelaine J; Bergot E; Zalcman G; Levallet G
    Target Oncol; 2022 Jul; 17(4):407-431. PubMed ID: 35906513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the biology of malignant pleural mesothelioma.
    Zucali PA; Ceresoli GL; De Vincenzo F; Simonelli M; Lorenzi E; Gianoncelli L; Santoro A
    Cancer Treat Rev; 2011 Nov; 37(7):543-58. PubMed ID: 21288646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New therapeutic strategies for malignant pleural mesothelioma.
    Bonelli MA; Fumarola C; La Monica S; Alfieri R
    Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging therapies in malignant pleural mesothelioma.
    Cinausero M; Rihawi K; Cortiula F; Follador A; Fasola G; Ardizzoni A
    Crit Rev Oncol Hematol; 2019 Dec; 144():102815. PubMed ID: 31670225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach.
    Lisini D; Lettieri S; Nava S; Accordino G; Frigerio S; Bortolotto C; Lancia A; Filippi AR; Agustoni F; Pandolfi L; Piloni D; Comoli P; Corsico AG; Stella GM
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on biology and management of mesothelioma.
    Asciak R; George V; Rahman NM
    Eur Respir Rev; 2021 Mar; 30(159):. PubMed ID: 33472960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Rocky Road from Preclinical Findings to Successful Targeted Therapy in Pleural Mesothelioma.
    Paajanen J; Bueno R; De Rienzo A
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro and In Vivo Antitumor Activity of [Pt(O,O'-acac)(γ-acac)(DMS)] in Malignant Pleural Mesothelioma.
    Muscella A; Vetrugno C; Cossa LG; Antonaci G; De Nuccio F; De Pascali SA; Fanizzi FP; Marsigliante S
    PLoS One; 2016; 11(11):e0165154. PubMed ID: 27806086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pleural mesothelioma (PMe): The evolving molecular knowledge of a rare and aggressive cancer.
    Rigon M; Mutti L; Campanella M
    Mol Oncol; 2024 Apr; 18(4):797-814. PubMed ID: 38459714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
    Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
    Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of preclinical models for malignant pleural mesothelioma.
    Shamseddin M; Obacz J; Garnett MJ; Rintoul RC; Francies HE; Marciniak SJ
    Thorax; 2021 Nov; 76(11):1154-1162. PubMed ID: 33692175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing.
    Hylebos M; Van Camp G; van Meerbeeck JP; Op de Beeck K
    J Thorac Oncol; 2016 Oct; 11(10):1615-26. PubMed ID: 27282309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesothelioma in situ with regressive malignant pleural effusion and an unexpected evolution: A case report.
    Almeida GC; Santos UP; Parente YDM; Colares PFB; Mizutani RF; Bernardi FDC; Terra RM; Terra-Filho M
    Am J Ind Med; 2022 Jul; 65(7):620-623. PubMed ID: 35524457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of failure following surgical resection for malignant pleural mesothelioma.
    Jänne PA; Baldini EH
    Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.
    Di Marzo D; Forte IM; Indovina P; Di Gennaro E; Rizzo V; Giorgi F; Mattioli E; Iannuzzi CA; Budillon A; Giordano A; Pentimalli F
    Cell Cycle; 2014; 13(4):652-65. PubMed ID: 24345738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.